
Baxter International Inc. (NYSE:BAX – Free Report) – Equities research analysts at Zacks Research decreased their Q4 2026 EPS estimates for shares of Baxter International in a research note issued on Thursday, November 19th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of $0.59 for the quarter, down from their prior forecast of $0.60. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $2.10 per share. Zacks Research also issued estimates for Baxter International’s Q1 2028 earnings at $0.44 EPS.
Baxter International (NYSE:BAX – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 6.23% and a positive return on equity of 16.23%. The business had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same period in the prior year, the business posted $0.69 earnings per share. Baxter International’s revenue for the quarter was up 5.0% compared to the same quarter last year.
Read Our Latest Stock Report on Baxter International
Baxter International Stock Performance
NYSE BAX opened at $25.38 on Friday. The company has a 50 day moving average of $24.64 and a 200-day moving average of $21.81. The company has a current ratio of 1.79, a quick ratio of 1.19 and a debt-to-equity ratio of 1.20. The firm has a market cap of $13.13 billion, a price-to-earnings ratio of -18.00, a PEG ratio of 3.73 and a beta of 0.68. Baxter International has a 1-year low of $15.73 and a 1-year high of $30.00.
Institutional Trading of Baxter International
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp purchased a new stake in Baxter International in the 2nd quarter worth approximately $26,000. Nemes Rush Group LLC raised its position in shares of Baxter International by 2,915.9% during the 3rd quarter. Nemes Rush Group LLC now owns 1,327 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 1,283 shares in the last quarter. Global Retirement Partners LLC lifted its holdings in shares of Baxter International by 45.8% in the 3rd quarter. Global Retirement Partners LLC now owns 1,566 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 492 shares during the last quarter. Jacobi Capital Management LLC bought a new stake in Baxter International during the 3rd quarter valued at about $51,000. Finally, Silver Grove Financial Group Inc. grew its position in shares of Baxter International by 28.8% during the 3rd quarter. Silver Grove Financial Group Inc. now owns 2,031 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 454 shares in the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.
Baxter International Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, November 27th will be paid a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, November 27th. Baxter International’s dividend payout ratio is -2.84%.
Recent Baxter International Headlines
These are some of the BAX headlines that stood out recently:
- Positive Sentiment: Zacks raised its FY2026, FY2027 and FY2028 EPS forecasts to $2.09, $2.02 and $2.15, respectively. It also increased estimates for Q3 and Q4 2027 and Q3 2028, signaling improved expectations for some periods. MarketBeat report
- Neutral Sentiment: The revisions were mixed overall, and Zacks kept its Hold rating. The adjustments are analyst forecasts rather than a change in Baxter’s business outlook or formal company guidance. MarketBeat report
- Negative Sentiment: Zacks lowered its EPS estimates for Q4 2026, Q1 and Q2 2027, and Q2 2028. These cuts suggest softer expectations in several nearer-term periods and offset some of the upward revisions. MarketBeat report
About Baxter International
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
Further Reading
- Five stocks we like better than Baxter International
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
